Allison Bratzel's Stock Ratings

Piper Sandler Analyst

Allison Bratzel is an analyst at Piper Sandler. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/16/2024

Overall Average Return

3.17%

Smart Score

56.5%

Overall Average Return Percentile

44th

Number of Ratings

27
Buy NowGet Alert
07/10/2024ROIVBuy Now
Roivant Sciences
$11.5590.55%$20 → $22MaintainsOverweightGet Alert
06/24/2024ARGXBuy Now
argenx
$461.9415.82%$522 → $535MaintainsOverweightGet Alert
06/17/2024ARGXBuy Now
argenx
$461.9413%$522 → $522MaintainsOverweightGet Alert
03/26/2024SRRKBuy Now
Scholar Rock Holding
$9.21204.02% → $28MaintainsOverweightGet Alert
03/26/2024HUMABuy Now
Humacyte
$8.70-54.02%$4 → $4MaintainsNeutralGet Alert
03/14/2024SLDBBuy Now
Solid Biosciences
$8.70129.89%$8 → $20UpgradeNeutral → OverweightGet Alert
03/08/2024HUMABuy Now
Humacyte
$8.70-54.02%$3 → $4MaintainsNeutralGet Alert
01/26/2024ARGXBuy Now
argenx
$461.9413%$518 → $522MaintainsOverweightGet Alert
01/18/2024ARGXBuy Now
argenx
$461.9412.14%$515 → $518MaintainsOverweightGet Alert
01/05/2024ROIVBuy Now
Roivant Sciences
$11.5573.23% → $20Initiates → OverweightGet Alert
12/21/2023ARGXBuy Now
argenx
$461.9411.49%$575 → $515MaintainsOverweightGet Alert
10/13/2023ABCLBuy Now
AbCellera Biologics
$3.25515.57% → $20Assumes → OverweightGet Alert
08/31/2023ARGXBuy Now
argenx
$461.9429.89%$595 → $600MaintainsOverweightGet Alert
07/24/2023ARGXBuy Now
argenx
$461.9424.48%$545 → $575MaintainsOverweightGet Alert
04/20/2023VECTBuy Now
VectivBio Holding
——$23 → $25MaintainsOverweightGet Alert
04/17/2023REPLBuy Now
Replimune Group
$10.81307.03% → $44Assumes → OverweightGet Alert
04/03/2023RIGLBuy Now
Rigel Pharmaceuticals
$10.07-80.14% → $20Assumes → NeutralGet Alert
04/03/2023SRRKBuy Now
Scholar Rock Holding
$9.21182.3% → $26Assumes → OverweightGet Alert
02/23/2023ARGXBuy Now
argenx
$461.942.83%$465 → $475MaintainsOverweightGet Alert
02/08/2023INCYBuy Now
Incyte
$64.2555.64% → $100MaintainsOverweightGet Alert
01/31/2023INCYBuy Now
Incyte
$64.2555.64% → $100Initiates → OverweightGet Alert
11/11/2022SLDBBuy Now
Solid Biosciences
$8.70-8.05%$15 → $8MaintainsNeutralGet Alert
08/26/2022ARGXBuy Now
argenx
$461.940.66%$450 → $465MaintainsOverweightGet Alert
07/25/2022ARGXBuy Now
argenx
$461.94-8%$415 → $425MaintainsOverweightGet Alert
05/27/2022ARGXBuy Now
argenx
$461.94-10.16%$375 → $415MaintainsOverweightGet Alert
05/19/2022SLDBBuy Now
Solid Biosciences
$8.70-77.01%$75 → $30MaintainsNeutralGet Alert
04/28/2022SLDBBuy Now
Solid Biosciences
$8.70-42.53%$90 → $75MaintainsNeutralGet Alert

Recent Analyst Stock Rating News

The Analyst Verdict: argenx In The Eyes Of 12 Experts
Key Takeaways From argenx Analyst Ratings
Where Roivant Sciences Stands With Analysts
The Analyst Landscape: 4 Takes On Roivant Sciences
Analysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuring
Monday, Kinnate Biopharma Inc (NASDAQ: KNTE) prioritized the exarafenib combination, KIN-8741, and discovery efforts around its 
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 vaccine candidate as a booster. 
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free